A research review published in JAMA Otolaryngology on September 3 found that GLP-1 receptor agonists may offer significant improvement in obstructive sleep apnea related to obesity, with the strongest signal for tirzepatide.

Tirzepatide is sold as Zepbound and Mounjaro, and unlike semaglutide it also acts on glucose-dependent insulinotropic polypeptide receptors. Zepbound is already FDA approved for moderate to severe obstructive sleep apnea in adults with obesity, which makes this review less a discovery than an accounting of how far the evidence has actually got.

Key numbers

In the SURMOUNT-OSA phase 3 trials, tirzepatide reduced the apnea-hypopnea index by 20 to 24 events per hour, with 42% to 50% of patients reaching disease remission. The reviewers also cite a clear dose-response between weight and airway obstruction: losing 10% of body weight is linked to a 26% reduction in AHI.

The review searched PubMed, the Cochrane Library, ClinicalTrials.gov and Google Scholar for work published between 2016 and 2025, including randomized trials, meta-analyses and observational studies reporting polysomnographic or validated patient-reported outcomes. Case reports were excluded.

Why the airway opens

The primary mechanism the authors identify is unglamorous: weight loss reduces fat around the neck, tongue and throat, which helps keep the airway open during sleep. Tongue fat reduction gets specific mention, and it is one of the more interesting details here.

Beyond that, the authors flag emerging work on respiratory control sensitivity, leptin signaling and anti-inflammatory effects on airway muscle. Much of that evidence comes from animal studies and needs further testing in humans, and the review says so rather than folding it into the headline finding. Improvements in AHI appeared as early as four weeks, before maximum weight loss, which the authors read as a hint that something more than pounds is involved.

What is still unsettled

The reviewers are explicit that CPAP remained the superior treatment, positioning GLP-1 therapy as an alternative or addition for people who cannot tolerate CPAP or who need to lose weight before surgery. Open questions include how long benefits last after treatment stops, whether the drugs help people without obesity, and long-term cost and cardiovascular effects.

Ruchir P. Patel, MD, a sleep medicine specialist who was not involved in the review, told Healthline that clinicians and patients should not conclude a cure has been found. "There are other factors involved in the development of OSA, including just structural anatomy unrelated to fat deposits that cannot be addressed by weight loss," he said.

Bottom line

The review synthesizes a real and reasonably well-powered effect, then declines to oversell it, which is the right call. Cost is the part nobody has solved: James J. Chao, MD, a weight loss specialist who was also not involved, told Healthline that GLP-1 treatment can run around $1,000 per month, with coverage depending on the codes a doctor can submit.